Your shopping cart is currently empty

PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development. |
| Synonyms | PF4942847, PF04942847, PF 4942847 |
| Molecular Weight | 516.3 |
| Formula | C20H18Cl2F3N7O2 |
| Cas No. | 1046859-34-0 |
| Smiles | O=C(NCC(F)(F)F)N1CC=2N=C(N=C(C=3C(Cl)=CC(Cl)=CC3OCCN4N=CC=C4)C2C1)N |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.